Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FAPI-FUSCC-07
- Development stage
- Unknown
- Lead developer
- Fudan University Shanghai Cancer Center
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-FAPI-FUSCC-07 is a novel fluorine-18-labeled fibroblast activation protein inhibitor (FAPI) developed as a radiotracer for positron emission tomography (PET) imaging. It specifically targets the fibroblast activation protein (FAP), which is highly expressed in cancer-associated fibroblasts within the tumor microenvironment of various cancers. Preclinical and first-in-human studies have demonstrated that 18F-FAPI-FUSCC-07 exhibits high stability, strong tumor uptake, prolonged retention, and superior image contrast compared to other FAP-targeted tracers such as 18F-FAPI-42 and 18F-FAPI-74. Its mechanism of action involves binding with high affinity to FAP on cancer-associated fibroblasts, enabling sensitive detection of tumors via PET imaging. The tracer has shown promise for broad oncologic applications due to its improved diagnostic precision and favorable pharmacokinetics[1][3][4].
- Other names
- FAPI-FUSCC-07FAPI-FUSCC07FAPI-FUSCC 07
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 18F-FAPI-FUSCC-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FAPI-FUSCC-07.